Filing Details

Accession Number:
0001140361-18-011285
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-03-01 17:03:06
Reporting Period:
2018-02-27
Accepted Time:
2018-03-01 17:03:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1367644 Emergent Biosolutions Inc. EBS Pharmaceutical Preparations (2834) 141902018
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1514588 Adam Havey 400 Professional Dr, Suite 400
Gaithersburg MD 20879
Evp, Business Operations No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-02-27 5,036 $0.00 31,082 No 4 A Direct
Common Stock Acquisiton 2018-02-27 5,036 $0.00 36,118 No 4 A Direct
Common Stock Disposition 2018-02-27 409 $49.64 35,709 No 4 F Direct
Common Stock Disposition 2018-02-28 811 $49.97 34,898 No 4 F Direct
Common Stock Disposition 2018-03-01 1,898 $49.50 33,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 A Direct
No 4 F Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy Acquisiton 2018-02-27 20,145 $49.64 20,145 $49.64
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
20,145 2025-02-26 No 4 A Direct
Footnotes
  1. Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.
  2. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
  3. Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2020 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period.
  4. Vests in three equal installments on February 26, 2019, February 26, 2020 and February 26, 2021.
  5. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey.